Vion Pharmaceuticals has reported a net loss of $6.6m or $0.83 per share for the second quarter of 2009, a decrease when compared to a net loss of $7.9m or $1.06 per share for the same period in 2008.
The company has reported a net loss of $10.9m or $1.37 per share for the six-month ended June 30, 2009, as compared to a net loss of $16.1m or $2.20 per share for the same period in 2008.
The company has reported total operating expenses of $4.9m for the second quarter ended June 30, 2009, a decrease when compared to $6.6m for the same period prior year.
The company has reported total operating expenses of $9.5m for the six months ended June 30,2009, a decrease when compared to 13.8m for the same period prior year.
Alan Kessman, CEO of Vion Pharmaceuticals, said: This is an exciting time for our company. We are preparing for the ODAC meeting at the beginning of September and looking forward to presenting our data to the Committee in support of Onrigin for its use as a new therapeutic agent for elderly poor-risk AML patients.